Mochi’s current medication pages make two crucial details visible: the membership costs extra, and the medication price can change with the prescribed dose. Keep both in the calculation before comparing a low starting quote.
- Care or fulfillment model
- Membership-based care
- Displayed price
- Sema advertised from $60
- Price boundary
- Medication starting quote; membership extra; dose-dependent
- Research date
- October 8, 2026
What stands out
- Separate medication pages identify compounded status
- A live video visit and ongoing care are described
- Explicit notice that medication is not included in membership
What to weigh
- Starting medicine prices are not complete program totals
- Prices may vary with the prescribed dose
- Compounded-product evidence differs from approved medicines
What the public quotes actually say
The reviewed semaglutide page showed a starting medication quote of $60, plus Mochi membership. The tirzepatide page showed $90, also plus membership. Both state that price varies based on the prescribed dose and that medicine cost is not part of the membership fee.[source][source]
We have not converted those numbers into a universal monthly all-in price. The membership term, medicine billing period, prescription and current offer must be confirmed together. A prominently displayed starting number is not enough to calculate the recurring total.
The care model behind the quote
Mochi describes a questionnaire, a live video visit, pharmacy coordination and ongoing care. The current site also describes medical and nutrition or wellness support. This review did not book a visit or measure availability.[source]
For a meaningful service comparison, ask which visits are included, how follow-ups are arranged and whether the same clinician continues your care. A large menu of services is less useful if the relevant appointment or support pathway is unclear.
These reviews cover compounded medicines
The two medication pages reviewed here are for compounded semaglutide and compounded tirzepatide. They are not FDA-approved finished products. FDA warns that compounded GLP-1 products have not undergone its review for safety, effectiveness and quality.[source]
The agency recommends their use only when medical needs cannot be met by an approved drug. Ask about that rationale and the dispensing pharmacy. Do not use a price difference to infer equivalence with Wegovy or Zepbound.[source]
Make the ongoing cost explicit
Request the membership charge today, its renewal amount and cadence, the medication charge at the prescribed dose, and any separate supply, shipping or laboratory expenses. Ask what happens financially if the clinician changes treatment.
If an annual membership is quoted as a monthly equivalent, record the upfront amount separately. The provider’s current checkout should resolve these details; this publication will not fill a missing number with an older price from another review.
How to compare Mochi
Mochi may be relevant when ongoing medical and nutrition support are priorities and a clinician is evaluating suitable treatment options. Compare the service structure with Ro or Hers separately from the drug comparison. The care fee and the medicine choice answer different questions.
The individual semaglutide and tirzepatide reviews explain what can be learned from each current product page. Customer testimonials, including compensated examples disclosed by the provider, are not independent efficacy evidence.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Accessed October 8, 2026.
- Mochi Health: current care modelProvider membership and care overview
- Mochi: compounded semaglutideStarting medication quote; dose-dependent; membership extra
- Mochi: compounded tirzepatideStarting medication quote; dose-dependent; membership extra
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags